



Prior Authorization Approval Criteria

Xerese (acyclovir 5% and hydrocortisone 1%)

Generic name:	acyclovir 5% and hydrocortisone 1%
Brand name:	Xerese
Medication class:	Topical
FDA-approved uses:	Topical treatment of herpes labialis (cold sores)
Available dosage forms:	Topical cream containing acyclovir 5% and hydrocortisone 1%
Usual dose:	Applied 5 times daily
Approximate monthly cost: (based on AWP 2011)	\$190.80
Duration of therapy:	5 days per outbreak

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Clinically diagnosed herpes labialis on the lips and around the mouth.
- Must be 12 years of age or older
- Failed topical acyclovir 5% cream
- Intolerance to using acyclovir 5% cream and hydrocortisone 1% simultaneously.

OR

- Inability to use two separate medications.

Contraindications:

- None

Not approved if:

- The patient has not tried acyclovir 5% cream and hydrocortisone 1% as separate products used simultaneously.
- Patient was non-compliant using acyclovir 5% cream and hydrocortisone 1% as separate products simultaneously.
- Product is being used for convenience.

Special considerations:

- No studies have been done to show that Xerese is superior to acyclovir 5% cream and hydrocortisone 1% when used as separate products but applied at the same time.

FCHP Pharmacy and Therapeutics Committee approval: _____

Adopted: 03/09/11